Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites

Drug Metabolism and Disposition - United States
doi 10.1124/dmd.116.071613
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Related search

Metabolism and Disposition of Tribendimidine and Its Metabolites in Healthy Chinese Volunteers

Drugs in R and D
Pharmacology
2010English

Characterization of a Novel Venetoclax Resistance Mutation (BCL2 Phe104Ile) Observed in Follicular Lymphoma

British Journal of Haematology
Hematology
2019English

Metabolic Changes Associated With Metformin Potentiates BCL-2 Inhibitor, Venetoclax, and CDK9 Inhibitor, BAY1143572 and Reduces Viability of Lymphoma Cells

Oncotarget
Oncology
2018English

Unusual Manifestation of Sweet's Syndrome in B-Cell Lymphoma

Acta Dermato-Venereologica
DermatologyMedicine
2003English

Development and Characterization of 5 Canine B-Cell Lymphoma Cell Lines

Leukemia Research
Cancer ResearchOncologyHematology
2012English

The BCL2 Inhibitor Venetoclax Is Active in Non-Hodgkin Lymphoma

Cancer Discovery
Oncology
2017English

Combination of Pim Kinase Inhibitor SGI-1776 and Bendamustine in B-Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Direct Comparison of (±) 3,4-Methylenedioxymethamphetamine (“Ecstasy”) Disposition and Metabolism in Squirrel Monkeys and Humans

Therapeutic Drug Monitoring
Pharmacology
2009English

The Disposition of Antipyrine and Its Metabolites in Young and Elderly Healthy Volunteers.

British Journal of Clinical Pharmacology
Pharmacology
1987English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy